Sulindac Sulfone Modulates β-Catenin in Human Cholesteatoma Cell Culture

Archives of Medical Research

Volumn 38, Issue 4, 2007, Pages 367-371

  Sauter, Alexander ^a   Matharu, Rubina ^b   Braun, Theresa ^a   Schultz, Johannes ^a   Sadick, Haneen ^a   Hormann, Karl ^a   Naim, Ramin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

catenin; Apoptosis; Cell culture; External auditory canal cholesteatoma; Keratinocyte

Indexed keywords

BETA CATENIN; SULINDAC SULFONE;

ARTICLE; CELL CULTURE; CHEMOPROPHYLAXIS; CHOLESTEATOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTERNAL AUDITORY CANAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MALE; PROTEIN CONTENT; WESTERN BLOTTING;

BETA CATENIN; BLOTTING, WESTERN; CELLS, CULTURED; CHOLESTEATOMA; EAR DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; SULINDAC;

EID: 34047150916     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.11.005     Document Type: Article

References (17)

1. Toynbee J.A. Specimen of molluscum contagiosum developed in the external auditory meatus. Lond Med Gazette (1850) 46811
2. Piepergerdes M.C., Kramer B.M., and Behnke E.E. Keratosis obturans and external auditory canal cholesteatoma. Laryngoscope 90 (1980) 383-391
3. Naim R., Sadick H., Bayerl C., Riedel F., Schafer C., Bran G., et al. Hepatocyte growth factor/scatter factor induces VEGF in human external auditory canal cholesteatoma cell culture. Int J Mol Med 15 (2005) 67-71
4. Naim R., Riedel F., Bran G., Sadick H., and Hormann K. Cell adhesion proteins in external auditory canal cholesteatoma. HNO 52 (2004) 1083-1087
5. Naim R., Riedel F., Bran G., and Hormann K. Expression of beta-catenin in external auditory canal cholesteatoma (EACC). Biofactors 19 (2003) 189-195
6. Wijnhoven B.P., Dinjens W.N., and Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87 (2000) 992-1005
7. Fukuda K. Apoptosis-associated cleavage of beta-catenin in human colon cancer and rat hepatoma cells. Int J Biochem Cell Biol 31 (1999) 519-529
8. Polakis P., Hart M., and Rubinfeld B. Defects in the regulation of beta-catenin in colorectal cancer. Adv Exp Med Biol (1999) 47023-47032
9. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57 (1997) 2452-2459
10. Goluboff E.T. Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Investig Drugs 10 (2001) 1875-1882
11. Zhang Y.W., Su Y., Volpert O.V., and Vande Woude G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100 (2003) 12718-12723
12. Naim R., and Linthicum Jr. F.H. External auditory canal cholesteatoma. Otol Neurotol 25 (2004) 412-413
13. Aberle H., Schwartz H., and Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 61 (1996) 514-523
14. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B., et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60 (2000) 3338-3342
15. Lim J.T., Piazza G.A., Han E.K., Delohery T.M., Li H., Finn T.S., et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58 (1999) 1097-1107
16. Rahman M.A., Dhar D.K., Masunaga R., Yamanoi A., Kohno H., and Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 60 (2000) 2085-2089
17. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn Jr. P.A., and Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59 (1999) 6178-6184